Obsidian Therapeutics
This role serves as a technical leader and hands-on scientist within the Technical Operations group, advancing analytical sciences capabilities to support late-stage clinical development and commercial readiness for viral vector therapies. The position involves leading the development, optimization, and lifecycle management of analytical methods while partnering with Quality Control and external laboratories to ensure method transfer and validation readiness. The successful candidate will collaborate across multiple functions to drive analytical development studies and provide technical expertise for assay qualification and lifecycle management.
Headquarters
Cambridge, Massachusetts, United States
Obsidian Therapeutics is a clinical-stage biotechnology company using its proprietary cytoDRiVE® platform to engineer novel TIL (tumor-infiltrating lymphocyte) cell therapies. The platform leverages drug-responsive domains (DRDs) to regulate protein function using an FDA-approved small-molecule drug. The company's lead program, OBX-115 (amsoki-cel), is being evaluated in advanced melanoma in a Phase 1/2 clinical trial.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Obsidian Therapeutics.
29% above the average for this role
Exec Director, Viral Vector Process Development
Gilead Sciences
Development Scientist III, Viral Vector Analytical Development
AstraZeneca
Director Vector Engineering
AstraZeneca
Associate Scientist II, Analytical Development (Protein-Based Assays)
Forge Biologics
Senior Scientist (Analytical Development, Cell Therapy)
AstraZeneca
Senior Scientist Vector Engineering
AstraZeneca